HOSPITAL UNIVERSITARIO RUBER

2024

1. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

   The Lancet, Vol. 403, Núm. 10437, pp. 1649-1659

2. A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative)

   Future oncology (London, England), Vol. 20, Núm. 11, pp. 635-651

3. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

   Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993

4. Adolescent Reference Values for MR-Derived Biventricular Strain Obtained Using Feature-Tracking and Myocardial Tagging

   Journal of Magnetic Resonance Imaging

5. AulaGinecología.com: A new educational tool in gynecology and obstetrics

   Educacion Medica, Vol. 25, Núm. 2

6. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis

   ESMO Open, Vol. 9, Núm. 3

7. Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial

   European Journal of Nuclear Medicine and Molecular Imaging

8. Confirmatory study of the usefulness of quantum molecular resonance and microdissectomy for the treatment of lumbar radiculopathy in a prospective cohort at 6 months follow-up

   Scandinavian Journal of Pain, Vol. 24, Núm. 1

9. Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119

   Journal of Pathology: Clinical Research, Vol. 10, Núm. 3

10. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab

    Breast Cancer Research and Treatment

11. Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis

    European Journal of Cancer, Vol. 202

12. Effect of a multidisciplinary team in the management of vascular access for hemodialysis

    Nefrologia

13. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)

    Radiotherapy and Oncology

14. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

    Annals of Oncology, Vol. 35, Núm. 5, pp. 429-436

15. Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer

    International Journal of Molecular Sciences, Vol. 25, Núm. 7

16. Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research

    Clinical Cancer Research, Vol. 30, Núm. 6, pp. 1093-1103

17. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations

    The Lancet Oncology, Vol. 25, Núm. 2, pp. e73-e83

18. Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Vol. 65, Núm. 5, pp. 708-713

19. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

20. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

    ESMO Open, Vol. 9, Núm. 3